Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
Postgrad Med
; 134(sup1): 18-27, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-36691308
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
Diabetes Mellitus, Type 2
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Postgrad Med
Year:
2022
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom